Ranibizumab (Lucentis®)

OFFICE ADMINISTRATION - Sterile Environment / Aseptic Technique

Indications for Prior Authorization:

  • Neovascular (WET) age related Macular Degeneration (AMD)
  • Macular edema secondary to retinal vein occlusion (RVO)
  • Diabetic macular edema (DME)

The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee:

  • Combination therapy with verteporfin (Visudyne®)
  • Any other diagnosis not listed in the approved indications

Dosing:

  • The dose of ranibizumab for AMD and RVO is not to exceed 0.5 mg (five units) once a month (28 days) by intravitreous injection.
  • The dose for DME is 0.3 mg once a month (28 days)

Monitoring:

  • Elevation in intraocular pressure
  • Ocular inflammation (endophthalmitis)
    • Immediately after injection check for perfusion of the optic nerve head
    • Measure intraocular pressure (tonometry) within 30 minutes following injection
    • Slit lamp biomicroscopy between 2 and 7 days following injection

 

Last review date: December 2, 2013

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.